The rise and fall of PSA: Clinical implications of prostate specific antigen kinetics

Urological Research

Volumn 30, Issue 2, 2002, Pages 85-88

  Semjonow, Axel ^a   Schmid, Hans Peter ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Kantonsspital St Gallen Klinik fur Urologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ANTIGEN DETECTION; ANTIGEN SPECIFICITY; BINDING KINETICS; CELL KINETICS; DISEASE MARKER; EDITORIAL; ELIMINATION REACTION; HALF LIFE TIME; HUMAN; MATHEMATICAL ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER;

HUMANS; KINETICS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0036938708     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00240-002-0238-5     Document Type: Editorial

References (35)

1. Akimoto S, Masai M, Akakura K, Shimazaki J (1995) Tumor marker doubling time in patients with prostate cancer: determination of prostate-specific antigen and prostatic acid phosphatase doubling time. Eur Urol 27: 207
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132: 474
3. Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, Labrousse F, Voitot H (1999) Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 45: 1695
4. Brändle E, Gottfried HW, Maier S, Flohr P, Steinbach G, Hautmann RE (1995) Ist die radikale Prostatektomie ein geeignetes Modell zur Bestimmung der PSA-Halbwertszeit? Urologe A 34: 419
5. Brändle E, Hautmann O, Bachem M, Kleinschmidt K, Gottfried HW, Grünert A, Hautmann RE (1999) Serum half-life time determination of free and total prostate-specific antigen following radical prostatectomy - a critical assessment. Urology 53: 722
6. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267: 2215
7. Di Federico G, Zezza A, Nicolai M, Lombardi G, Cipollone G, Iantorno R, Boni R, Tenaglia R (1997) Vita media del PSA sierico dopo prostatectomia radicale. Correlazione con lo stadio patologico e l'evoluzione clinica della malat. Arch Ital Urol Androl 69: 97
8. Egawa S, Ohori M, Iwamura M, Kuwao S, Baba S (1999) Efficacy and limitations of delayed/salvage radiation therapy after radical prostatectomy. BJU Int 84: 815
9. Gastineau CF, Albert A, Randall LM (1949) The renal clearance of chorionic gonadotropic hormone in pregnancy, in neoplasm of the testis and in hydatidiform mole. J Clin Endocrinol Metab 9: 615
10. Gion M, Mione R, Barioli P, Dittadi R (1996) Dynamic use of tumor markers, rationale-clinical applications and pitfalls. Anticancer Res 16: 2279
11. Hamm M, Semjonow A, Oberpenning F, Mandt S, Rathert P (1996) Eliminationskinetik des prostataspezifischen Antigens als Prognosefaktor nach radikaler Prostatektomie. Akt Urol 27: 385
12. Huber PR, Mattarelli G, Strittmatter B, van Steenbrugge GJ, Schmid HP, Maurer A (1995) In vivo and in vitro complex formation of prostate specific antigen with alpha 1-anti-chymotrypsin. Prostate 27: 166
13. Lamerz R, Albrecht W, Bialk P, Gerl A, Schmid HP, Semjonow A, van Poppel H (1999) Tumour markers in germ cell cancer: EGTM recommendations. European Group on Tumour Markers. Anticancer Res 19: 2795
14. Leibman BD, Dillioglugil O, Scardino PT, Abbas F, Rogers E, Wolfinger RD, Kattan MW (1998) Prostate-specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: a novel analysis. J Clin Oncol 16: 2267
15. Lein M, Brux B, Jung K, Henke W, Koenig F, Stephan C, Schnorr D, Loening SA (1997) Elimination of serum free and total prostate-specific antigen after radical retropubic prostatectomy. Eur J Clin Chem Clin Biochem 35: 591
16. Lilja H, Haese A, Björk T, Friedrich MG, Piironen T, Pettersson K, Huland E, Huland H (1999) Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy. J Urol 162: 2029
17. Mikolajczyk SD, Grauer LS, Millar LS, Hill TM, Kumar A, Rittenhouse HG, Wolfert RL, Saedi MS (1997) A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 50: 710
18. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Marks LS, Song W, Wheeler TM, Slawin KM (2000) A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 60: 756
19. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Wolfert RL, Marks LS, Song W, Wheeler TM, Slawin KM (2000) "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55: 41
20. Oberpenning F, Surdel W, Weining C, Pühse G, Hertle L, Semjonow A (1998) Post-manipulatory increase and decline of different forms of prostate-specific antigen during removal of the prostate. Tumour Biol 19: 23
21. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC, Brendler CB, Walsh PC (1988) Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 139: 766
22. Pontes JE, Foemmel R, Jabalameli P, Howard PD, Montie J, Boyett J (1990) Prognostic implications of disappearance rate of biologic markers following radical prostatectomy. Urology 36: 415
23. Price CP, Allard J, Davies G, Dawnay ADMJ, France M, Mandarino G, Ward AM, Patel B, Sibley P, Sturgeon C (2001) Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. Ann Clin Biochem 38: 188
24. Ravery V, Meulemans A, Boccon-Gibod L (1998) Clearance of free and total serum PSA after prostatic surgery. Eur Urol 33: 251
25. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW (1998) Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 35: 275
26. Schifman RB (1993) Prostate-specific antigen half life. Lab Med 3: 2
27. Schmid HP, McNeal JE, Stamey TA (1993) Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 71: 2031
28. Schmid HP, Semjonow A, Maibach R (1999) Prostate-specific antigen doubling time: a potential surrogate end point in hormone-refractory prostate cancer. J Clin Oncol 17: 1645
29. Schröder FH, Kranse R, Barbet N, Hop WC, Kandra A, Lassus M (2000) Prostate-specific antigen: A surrogate end-point for screening new agents against prostate cancer? Prostate 42: 107
30. Semjonow A, Brandt B, Oberpenning F, Roth S, Hertle L (1996) Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate 7: 3
31. Semjonow A, Hamm M, Rathert P (1992) Half-life of prostate-specific antigen after radical prostatectomy: The decisive predictor of curative treatment? Eur Urol 21: 200
32. Semjonow A, Hamm M, Rathert P (1994) Elimination kinetics of prostate-specific antigen: serum and urine. Int J Biol Markers 9: 15
33. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909
34. Stenman UH (1996) Re: Free-to-total prostate specific antigen ratio as a single test for detection of significant stage Tlc prostate cancer. J Urol 156: 1047
35. Stephan C, Jung K, Brux B, Lein M, Sinha P, Schnorr D, Loening SA (2000) ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulation. Urology 55: 560